Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
- PMID: 31971676
- DOI: 10.1056/NEJMoa1901229
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
Abstract
Background: In September 2015, the United Kingdom introduced the multicomponent meningococcal group B vaccine (4CMenB, Bexsero) into its publicly funded national immunization program at a reduced two-dose priming schedule for infants, with a 12-month booster.
Methods: Using data from enhanced national surveillance of invasive meningococcal disease in England, we evaluated the effect of vaccination on the incidence of meningococcal group B disease during the first 3 years of the program. The effect of vaccination was assessed by comparing the observed incidence of disease with the expected incidence based on the incidence during the 4-year prevaccination period in equivalent cohorts and with the use of disease trends in cohorts of children younger than 5 years of age who were not eligible to receive the vaccine. Vaccine effectiveness was estimated with the use of the indirect screening method.
Results: 4CMenB uptake in England remained consistently high; data from the first 3 months of 2018 showed that 92.5% of children had completed the primary immunizations by their first birthday and 87.9% had received all three doses by 2 years. From September 2015 through August 2018, the incidence of meningococcal group B disease in England (average annual birth cohort, approximately 650,000 infants) was significantly lower in vaccine-eligible cohorts than the expected incidence (63 observed cases as compared with 253 expected cases; incidence rate ratio, 0.25; 95% confidence interval [CI], 0.19 to 0.36), with a 75% reduction in age groups that were fully eligible for vaccination. The adjusted vaccine effectiveness against meningococcal group B disease was 52.7% (95% CI, -33.5 to 83.2) with a two-dose priming schedule for infants and 59.1% (95% CI, -31.1 to 87.2) with a two-dose priming schedule plus a booster at 1 year). Over the 3-year period, there were 169 cases of meningococcal group B disease in the vaccine-eligible cohorts, and an estimated 277 cases (95% CI, 236 to 323) were prevented.
Conclusions: The 4CMenB program was associated with continued positive effect against meningococcal group B disease in children in England, and protection after three doses of the vaccine was sustained for at least 2 years. (Funded by Public Health England.).
Copyright © 2020 Massachusetts Medical Society.
Comment in
-
Good News and Bad News - 4CMenB Vaccine for Group B Neisseria meningitidis.N Engl J Med. 2020 Jan 23;382(4):376-378. doi: 10.1056/NEJMe1916440. N Engl J Med. 2020. PMID: 31971684 No abstract available.
Similar articles
-
Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.Lancet. 2016 Dec 3;388(10061):2775-2782. doi: 10.1016/S0140-6736(16)31921-3. Epub 2016 Oct 27. Lancet. 2016. PMID: 28100432
-
A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model.BMC Infect Dis. 2021 Dec 11;21(1):1244. doi: 10.1186/s12879-021-06906-x. BMC Infect Dis. 2021. PMID: 34895161 Free PMC article.
-
Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.Vaccine. 2022 Mar 1;40(10):1493-1498. doi: 10.1016/j.vaccine.2021.12.010. Epub 2022 Feb 8. Vaccine. 2022. PMID: 35148913
-
4CMenB journey to the 10-year anniversary and beyond.Hum Vaccin Immunother. 2024 Dec 31;20(1):2357924. doi: 10.1080/21645515.2024.2357924. Epub 2024 Jul 8. Hum Vaccin Immunother. 2024. PMID: 38976659 Free PMC article. Review.
-
Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.BioDrugs. 2013 Jun;27(3):263-74. doi: 10.1007/s40259-013-0029-2. BioDrugs. 2013. PMID: 23575646 Review.
Cited by
-
Risk of Invasive Meningococcal Disease in Preterm Infants.Open Forum Infect Dis. 2024 Apr 15;11(4):ofae164. doi: 10.1093/ofid/ofae164. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38665170 Free PMC article.
-
Mucosal adjuvanticity and mucosal booster effect of colibactin-depleted probiotic Escherichia coli membrane vesicles.Hum Vaccin Immunother. 2024 Dec 31;20(1):2337987. doi: 10.1080/21645515.2024.2337987. Epub 2024 Apr 24. Hum Vaccin Immunother. 2024. PMID: 38658133 Free PMC article.
-
Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany.Infect Dis Ther. 2024 Apr;13(4):907-920. doi: 10.1007/s40121-024-00958-7. Epub 2024 Apr 4. Infect Dis Ther. 2024. PMID: 38570446 Free PMC article.
-
4CMenB Vaccination to Prevent Meningococcal B Disease in Vietnam: Expert Review and Opinion.Infect Dis Ther. 2024 Mar;13(3):423-437. doi: 10.1007/s40121-023-00905-y. Epub 2024 Mar 2. Infect Dis Ther. 2024. PMID: 38430327 Free PMC article.
-
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.Euro Surveill. 2024 Feb;29(6):2400046. doi: 10.2807/1560-7917.ES.2024.29.6.2400046. Euro Surveill. 2024. PMID: 38333937 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical